[Federal Register Volume 64, Number 198 (Thursday, October 14, 1999)]
[Notices]
[Pages 55738-55739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-26752]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration
[HCFA-3023-N]


Medicare Program; Meeting of the Laboratory and Diagnostic 
Services Panel of the Medicare Coverage Advisory Committee--November 15 
and 16, 1999

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a meeting of the Laboratory and 
Diagnostic Services Panel (the Panel) of the Medicare Coverage Advisory 
Committee. The Panel will discuss presentations from interested persons 
regarding human tumor assay systems. This meeting is open to the public 
and complies with the Federal Advisory Committee Act (5 U.S.C. App. 2, 
section 10(a)(1) and (a)(2)).

DATES: The Meeting: November 15, 1999 from 8 a.m. to 4 p.m. and on 
November 16, 1999, from 8 a.m. to 12 noon, E.S.T.

[[Page 55739]]

    Deadline for Presentation Submissions: November 1, 1999.
    Deadline for Submission of Final Comments: November 30, 1999.

ADDRESSES: The Meeting: The meeting will be held at the Sheraton Inner 
Harbor at 300 South Charles Street, Baltimore, MD 21201.
    Presentations and Comments: Submit written presentations and 
comments to Katherine Tillman, Executive Secretary; Office of Clinical 
Standards and Quality, Health Care Financing Administration, 7500 
Security Boulevard, Mail Stop S3-02-01, Baltimore, MD 21244.

FOR FURTHER INFORMATION CONTACT: Katherine Tillman, Executive 
Secretary, (410) 786-9252.

SUPPLEMENTARY INFORMATION: We have established the Medicare Coverage 
Advisory Committee (MCAC) to provide advice and recommendations to us 
about clinical coverage issues. The MCAC is composed of an Executive 
Committee and six panels, each containing members with expertise in one 
or more of the following fields: clinical and administrative medicine, 
biologic and physical sciences, public health administration, health 
care data and information management and analysis, the economics of 
health care, medical ethics, and other related professions. Each panel 
is composed of a chairperson, voting members, a nonvoting consumer 
representative, and a nonvoting industry representative.

Current Members of the Panel

    John H. Ferguson, M.D. (Chairperson); Robert L. Murray, Ph.D.; 
David N. Sundwall, M.D.; George G. Klee, M.D., Ph.D.; Paul D. Mintz, 
M.D.; Richard J. Hausner, M.D.; Mary E. Kass, M.D.; E. Conyers O'Bryan, 
M.D.; Cheryl J. Kraft, M.S.; Neysa R. Simmers, M.B.A.; John J.S. 
Brooks, M.D.; Paul M. Fischer, M.D.; Kathyrn A. Snow, M.H.A.; James 
(Rod) Barnes, M.B.A.

Topic of the Meeting

    The Panel will discuss presentations from interested persons 
regarding human tumor assay systems.

Procedure and Agenda

    On day 1 of the meeting, the Panel will hear oral presentations 
from the public for approximately 3 hours and 15 minutes. The Panel may 
limit the number and duration of oral presentations to the time 
available. If you wish to make a presentation during one of these 
sessions, you must submit the following to the Executive Secretary 
before the Deadline for Presentation Submissions date listed in the 
DATES section of this notice: a brief statement of the general nature 
of the evidence or arguments you wish to present, the names and 
addresses of proposed participants, and an estimate of the time 
required to make the presentation. We will request that you declare at 
the meeting whether or not you have any financial involvement with 
manufacturers of any items or services being discussed (or with their 
competitors).
    After the public presentation on Day 1 of the meeting, we will make 
a presentation to the Panel. After our presentation, the Panel will 
deliberate openly on the topic. Interested persons may observe the 
deliberations, but the Panel will not hear further comments during this 
time except at the request of the chairperson. At the end of the Panel 
deliberations, the Panel will allow a 30-minute open public session for 
any attendee to address issues specific to the topic.

Submission of Final Comments

    Interested persons not scheduled to make an oral presentation, 
unable to attend the meeting, or wishing to make further remarks, may 
submit written comments to the Executive Secretary by the Deadline for 
Submission of Final Comments in the DATES section of this notice.

HCFA Home Page

    You may access detailed information regarding the agenda and 
schedule of presentations on our home page www.hcfa.gov/quality/8b.htm 
the day after the Deadline for Presentation Submissions in the DATES 
section of this notice.

    Authority: 5 U.S.C. App. 2, section 10(a)(1) and (a)(2).

(Catalog of Federal Domestic Assistance Program No. 93.774, 
Medicare--Supplementary Medical Insurance Program)

    Dated: October 6, 1999.
Jeffrey L. Kang,
Director, Office of Clinical Standards and Quality, Health Care 
Financing Administration.
[FR Doc. 99-26752 Filed 10-13-99; 8:45 am]
BILLING CODE 4120-01-P